Circulating endothelial progenitor cells in systemic sclerosis: Relation to impaired angiogenesis and cardiovascular manifestations

Clinical and Experimental Rheumatology

Volumn 26, Issue 3, 2008, Pages 421-429

  Nevskaya, Tatiana ^a,b   Bykovskaia, Svetlana ^a   Lyssuk, Elena ^a   Sakhov, Ilia ^a   Zaprjagaeva, Marina ^a   Mach, Evelina ^a   Ananirva, Lidia ^a   Guseva, Natalia ^a   Nassonov, Evgeny ^a  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^b NONE   (Russian Federation)

Author keywords

Angiogenesis; Cardiovascular disease; Endothelial dysfunction; Endothelial progenitor cells; Systemic sclerosis

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FAS ANTIGEN; METHOTREXATE; PENICILLAMINE; VASCULOTROPIN RECEPTOR 2;

ADULT; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HEART DISEASE; HUMAN; HUMAN CELL; MICROANGIOPATHY; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STEM CELL; SYSTEMIC SCLEROSIS;

ADULT; ANTIGENS, CD; ANTIGENS, CD34; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PREVALENCE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; STEM CELLS;

EID: 48949117140     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. STRELHOW D, KORN JH: Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998; 10: 572-78.
2. MATUCCI CERINIC M, KAHALEH BM, LE ROY EC: The vascular involvement in systemic sclerosis. In FURST D, CLEMENTS P (Eds.) Systemic sclerosis. Philadelphia: Lea and Febiger, 1995; 513-74.
3. KAHALEH B: Lymphocyte interactions with the vascular endothelium in systemic sclerosis. Clin Dermatol 1994; 12: 361-67.
4. PRESCOTT RJ, FREEMONT AJ, JONES CJP et al.: Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255-63.
5. GILL M, DIAS S, HATTORI K et al.: Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001; 88: 167-74.
6. HRISTOV M, WEBER C: Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498-08.
7. RAFII S, LYDEN D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9: 702-12.
8. ASAHARA T, MUROHARA T, SULLIVAN A et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-67.
9. TAKAHASHI T, KALKA C, MASUDA H et al.: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-38.
10. FADINI G, SCHIAVON M, CANTINI M et al.: Circulating Progenitor Cells Are Reduced in Patients with Severe Lung Disease. Stem Cells 2006; 24: 1806-13. Published online April 6, 2006.
11. GEORGE J, GOLDSTEIN E, ABASHIDZE S et al.: Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 2004; 25: 1003-8.
12. HILL J, ZALOS G, HALCOX J et al.: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
13. VALGIMIGLI M, RIGOLIN GM, FUCILI A et al.: CD34 and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004; 110: 1209-12.
14. DEL PAPA N, COLOMBO G, FRACCHIOLLA N et al.: Circulating Endothelial Cells as a Marker of Ongoing Vascular Disease in Systemic Sclerosis. Arthritis Rheum 2004; 50: 1296-1304.
15. DEL PAPA N, QUIRICI N, SOLIGO D et al.: Bone marrow progenitors are defective in systemic sclerosis. Arthritis Rheum 2006; 54: 2608-15.
16. KUWANA M, OKAZAKI Y, YASUOKA H et al.: Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-10.
17. ALLANORE Y, BATTEUX F, AVOUAC J et al. Levels of circulating endothelial progenitor cells in systemic scleosis. Clin Exp Rheumatol 2007; 25: 60-6.
18. GUSEVA NG: Systemic sclerosis in rheumatic diseases (Ed. NASSONOV EL). Moscow: Medical Press 1997, 172-180.
19. LE ROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
20. MEDSGER TA, STEEN VD: Classification, prognosis. In CLEMENTS PJ, FURST DE (Eds.) Systemic sclerosis. Baltimore, MD: Williams & Wilkins 1996, 51-79.
21. CLEMENTS P, LACHENBRUCH P, SEIBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-85.
22. VALENTINI G, DELLA ROSSA A, BOMBARDIERI S et al.: European multicentre study of define disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
23. MEDSGER TA, SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
24. STEEN VD, MEDSGER TA JR: The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984-91.
25. MERKEL P, HERLYN K, MARTIN R et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410-20.
26. CUTOLO M, SULLI A, PIZZORNI C, ACCARDO S: Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000; 27: 155-60.
27. WERNER N, NICKENIG G: Influence of cardiovascular risk factors on endothelial progenitor cells limitations for therapy? Arteriosclerosis, Arterioscler Thromb Vasc Biol 2006; 26: 257.
28. KONDO T, HAYASHI M, TAKESHIDA K et al.: Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 2004; 24: 1-6.
29. LAMBIASE PD, EDWARDS RJ, ANTHOPOULOS P et al.: Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation 2004; 109: 2993-99.
30. LEUNG DW, CACHIANES G, KUANG W-J et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
31. HATTORI K, DIAS S, HEISSIG B et al.: Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193: 1005-14.
32. DISTLER O, DEL ROSSO A, GIACOMELLI R et al.: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4: R11.
33. DISTLER O, DISTLER JH, SCHEID A et al.: Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109-16.
34. SGONC R, GRUSCHWITZ MS, DIETRICH H et al.: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. Clin Invest 1996; 98: 785-92.
35. LUNARDI C, BASON G, CORROCHER R et al.: Induction of endothelial cell damage by hCMV molecular mimicry. Trends Immunol 2005; 26: 19-24.
36. SGONC R, GRUSCHWITZ MS, BOECK G et al.: Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-medoated cytotoxity via CD95. Arthritis Rheum 2000; 43: 2550-62.
37. BAUER S, GOLDSTEIN L, BAUER R et al.: The bone marrow-derived endothelial progenitor cell response is impaired in delayed wound healing from ischemia. J Vasc Surg 2006; 43: 134-41.
38. TAO J, JIN YF, YANG Z et al.: Reduced arterial elasticity is associated with endothelial dysfunction in persons of advancing age: comparative study of noninvasive pulse wave analysis and laser Doppler blood flow measurement. Am J Hypertens 2004; 17: 654-59.
39. BUDHIRAJA R, TUDER RM, HASSOUN PM: Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-65.
40. CELLA G, BELLOTTO F, TONA F et al.: Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120: 1226-30.
41. SATO K, KAGAYA Y, NAKANO M et al.: Important role of endogenous erythropoietin system in recruitment of EPCs in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-50.
42. ZHAO Y, COURTMAN D, DENG Y et al.: Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelium-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005; 96: 442-50.
43. ZAMMATETTI P, ZISCH AH: Adult 'endothelial progenitor cells' renewing vasculature. Int J Biochem Cell Biol 2005; 37: 493-503.
44. HUANG PP, LI SZ, HAN MZ et al.: Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb Haemost 2004; 91: 606-9.
45. TATEISHI-YUYAMA E, MATSUBARA H, MUROHARA T et al.: Therapeutic Angiogenesis using Cell Transplantation (TACT) Study investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-35.